In vivo h-VEGF165 gene transfer improves early endothelialisation and patency in synthetic vascular grafts☆

Lahtinen, Mika; Blomberg, Pontus; Baliulis, Giedrius; Carlsson, Fredrik; Khamis, Harry J.; Zemgulis, Vitas

doi:10.1016/j.ejcts.2006.11.048

Cited by 22 publications

(13 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The mechanism for this regulation is thought to be accelerated re-endothelialization of the injured vessels [75], increased NO production [76], and communication with other growth factor pathways [77]. VEGF is also known to be a key initiator molecule for vascular determination [5, 10]; thus, VEGF manipulation in vein grafts may protect venous-specific biology during adaptation.…”

Section: Algorithm Of Pathological Vein Graft Wall Thickeningmentioning

confidence: 99%

Mechanisms of Vein Graft Adaptation to the Arterial Circulation

Muto

Model

Ziegler

et al. 2010

Circ J

116

View full text Add to dashboard Cite

For patients with coronary artery disease or limb ischemia, placement of a vein graft as a conduit for a bypass is an important and generally durable strategy among the options for arterial reconstructive surgery. Vein grafts adapt to the arterial environment; limited formation of intimal hyperplasia in the vein graft wall is thought to be an important component of successful vein graft adaptation. However, it is also known that abnormal, or uncontrolled, adaptation may lead to abnormal vessel wall remodeling with excessive neointimal hyperplasia, and ultimately vein graft failure and clinical complications. Therefore, understanding the venous-specific pathophysiological and molecular mechanisms of vein graft adaptation are important for clinical vein graft management. Of particular importance, it is currently unknown whether several specific distinct molecular differences in venous mechanisms of adaptation exist that are distinct from arterial post-injury responses; in particular, the participation of the venous marker Eph-B4 and the vascular protective molecule Nogo-B may be involved in mechanisms of vessel remodeling specific to the vein. In this review, we describe 1) venous biology from embryonic development to the mature quiescent state; 2) sequential pathologies of vein graft neointima formation; and 3) novel candidates for strategies of vein graft management. We believe that the scientific inquiry of venous-specific adaptation mechanisms will ultimately provide improvements in vein graft outcomes.

show abstract

Section: Algorithm Of Pathological Vein Graft Wall Thickeningmentioning

confidence: 99%

Mechanisms of Vein Graft Adaptation to the Arterial Circulation

Muto

Model

Ziegler

et al. 2010

Circ J

116

View full text Add to dashboard Cite

show abstract

“…Earlier studies determined that angiogenic response to various graft materials depends partly on the material's porosity 3, 4. Moreover, ingrowth of endothelial cells (EC) in a vascular construct may enhance graft patency,5 and capillary ingrowth supports endothelialization of vascular grafts 6–8…”

Section: Introductionmentioning

confidence: 99%

Intravital fluorescent microscopic evaluation of bacterial cellulose as scaffold for vascular grafts

Esguerra

Fink

Laschke

et al. 2009

J Biomedical Materials Res

View full text Add to dashboard Cite

Although commonly used synthetic vascular grafts perform satisfactorily in large caliber blood vessels, they are prone to thrombosis in small diameter vessels. Therefore, small vessels might benefit from tissue engineered vascular grafts. This study evaluated bacterial cellulose (BC) as a potential biomaterial for biosynthetic blood vessels. We implanted the dorsal skinfold chambers in three groups of Syrian golden hamsters with BC (experimental group), polyglycolic acid, or expanded polytetrafluorethylene (control groups). Following implantation, we used intravital fluorescence microscopy, histology, and immunohistochemistry to analyze the biocompatibility, neovascularization, and incorporation of each material over a time period of 2 weeks. Biocompatibility was good in all groups, as indicated by the absence of leukocyte activation upon implantation. All groups displayed angiogenic response in the host tissue, but that response was highest in the polyglycolic acid group. Histology revealed vascularized granulation tissue surrounding all three biomaterials, with many proliferating cells and a lack of apoptotic cell death 2 weeks after implantation. In conclusion, BC offers good biocompatibility and material incorporation compared with commonly used materials in vascular surgery. Thus, BC represents a promising new biomaterial for tissue engineering of vascular grafts.

show abstract

“…The VEGF gene has been extensively studied and used to promote revascularization and re-endothelialization by stimulating endothelial progenitor cell migration and maturation 199,200. Thus, it has attracted attention as a DES candidate for its ability to promote endothelial regeneration while reducing in-stent neointimal areas in animal models 124.…”

Section: Nanoparticle Gene-eluting Stentsmentioning

confidence: 99%

Nanoparticle Drug- and Gene-eluting Stents for the Prevention and Treatment of Coronary Restenosis

Yin¹,

Dezhai²,

Wu³

2014

Theranostics

121

View full text Add to dashboard Cite

Percutaneous coronary intervention (PCI) has become the most common revascularization procedure for coronary artery disease. The use of stents has reduced the rate of restenosis by preventing elastic recoil and negative remodeling. However, in-stent restenosis remains one of the major drawbacks of this procedure. Drug-eluting stents (DESs) have proven to be effective in reducing the risk of late restenosis, but the use of currently marketed DESs presents safety concerns, including the non-specificity of therapeutics, incomplete endothelialization leading to late thrombosis, the need for long-term anti-platelet agents, and local hypersensitivity to polymer delivery matrices. In addition, the current DESs lack the capacity for adjustment of the drug dose and release kinetics appropriate to the disease status of the treated vessel. The development of efficacious therapeutic strategies to prevent and inhibit restenosis after PCI is critical for the treatment of coronary artery disease. The administration of drugs using biodegradable polymer nanoparticles as carriers has generated immense interest due to their excellent biocompatibility and ability to facilitate prolonged drug release. Despite the potential benefits of nanoparticles as smart drug delivery and diagnostic systems, much research is still required to evaluate potential toxicity issues related to the chemical properties of nanoparticle materials, as well as to their size and shape. This review describes the molecular mechanism of coronary restenosis, the use of DESs, and progress in nanoparticle drug- or gene-eluting stents for the prevention and treatment of coronary restenosis.

show abstract

In vivo h-VEGF165 gene transfer improves early endothelialisation and patency in synthetic vascular grafts☆

Abstract: Thus, these data suggested that endothelialisation was fastest in pre-clotted polyester grafts; and that local application of plasmids encoding for human vascular endothelial growth factor had a potential to improve early endothelialisation and patency in synthetic vascular grafts.

Cited by 22 publications

References 26 publications

Mechanisms of Vein Graft Adaptation to the Arterial Circulation

Mechanisms of Vein Graft Adaptation to the Arterial Circulation

Intravital fluorescent microscopic evaluation of bacterial cellulose as scaffold for vascular grafts

Nanoparticle Drug- and Gene-eluting Stents for the Prevention and Treatment of Coronary Restenosis

Contact Info

Product

Resources

About